Shots:
- AstraZeneca has entered a worldwide exclusive research collaboration & licensing agreement with insitro to discover novel targets and advance therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies using AI
- As per the deal, insitro will receive $40M upfront and is eligible for up to ~$1.46B in discovery, development & commercial milestones, plus single-digit royalties on global net sales; AstraZeneca holds exclusive worldwide rights to advance selected programs
- insitro will apply its Virtual Human AI platform to identify causal disease biology and advance AstraZeneca-nominated targets from discovery through to development candidate, while AstraZeneca will lead clinical development, regulatory work & commercialization
Ref: Businesswire | Image: AstraZeneca & Insitro | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
